Literature DB >> 11713353

Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP).

N Mogulkoc1, M H Brutsche, P W Bishop, B Murby, M S Greaves, A W Horrocks, M Wilson, C McCullough, M Prescott, J J Egan.   

Abstract

BACKGROUND: Clearance of inhaled technetium 99m-labelled diethylenetriamine penta-acetic acid ((99m)Tc-DTPA) from the lungs is a potential indicator of disease progression in patients with idiopathic pulmonary fibrosis (IPF).
METHODS: We prospectively analysed the usefulness of this technique for predicting survival in 106 non-smoking patients with usual interstitial pneumonia (UIP) pattern IPF diagnosed by high resolution CT (HRCT) scanning or histological examination (M/F 65/41, mean (SD) age 61 (11) years). DTPA clearance was analysed according to both mono-exponential and bi-exponential models. Half times for the fast (t(0.5)F) and slow (t(0.5)S) components of clearance, the percentage contribution of the fast component (fF), and half time for mono-exponential approximation to the early part of the clearance curve (t(0.5)) were calculated.
RESULTS: The patients had substantially faster t(0.5) (mean 23.9 (9.6) minutes) than normal values (>45 minutes). Thirty seven patients (35%) died during follow up (median 15 months). Univariate Cox regression analysis identified significant predictors of survival as age, forced expiratory volume in 1 second (FEV(1)), forced vital capacity (FVC), total lung capacity (TLC), % predicted TLC, carbon monoxide transfer factor (TLCO), % predicted TLCO, arterial oxygen tension (PaO(2)), oxygen saturation, t(0.5)F, and HRCT fibrosis score. Multiple stepwise Cox regression analysis identified t(0.5)F (p=0.03, hazard ratio 0.747, 95% CI 0.578 to 0.964), % predicted TLC (p=0.02, hazard ratio 0.976, 95% CI 0.956 to 0.995), % predicted TLCO (p=0.003, hazard ratio 0.960, 95% CI 0.935 to 0.986), and age (p=0.003, hazard ratio 1.062, 95% CI 1.021 to 1.104) as independent predictors of survival.
CONCLUSION: These data suggest that (99m)Tc-DTPA clearance t(0.5)F measurement may predict survival in patients with UIP pattern IPF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713353      PMCID: PMC1745984          DOI: 10.1136/thorax.56.12.916

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

1.  Clearance of 99mTc-DTPA in pigeon fancier's hypersensitivity pneumonitis.

Authors:  S J Bourke; S W Banham; J H McKillop; G Boyd
Journal:  Am Rev Respir Dis       Date:  1990-11

2.  [Pulmonary epithelial permeability in normal subjects and patients with idiopathic interstitial pneumonia].

Authors:  Y Anazawa; T Isawa; T Teshima; M Miki; M Motomiya
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1991-11

Review 3.  Pulmonary clearance of 99mTc-DTPA: a noninvasive assessment of epithelial integrity.

Authors:  H O'Brodovich; G Coates
Journal:  Lung       Date:  1987       Impact factor: 2.584

4.  Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation.

Authors:  N L Müller; C A Staples; R R Miller; S Vedal; W M Thurlbeck; D N Ostrow
Journal:  Radiology       Date:  1987-12       Impact factor: 11.105

5.  Fibrosing alveolitis: CT-pathologic correlation.

Authors:  N L Müller; R R Miller; W R Webb; K G Evans; D N Ostrow
Journal:  Radiology       Date:  1986-09       Impact factor: 11.105

6.  Radioaerosol lung clearance in patients with active pulmonary sarcoidosis.

Authors:  M P Jacobs; R P Baughman; J Hughes; M Fernandez-Ulloa
Journal:  Am Rev Respir Dis       Date:  1985-05

7.  Usual interstitial pneumonia: histologic correlation with high-resolution CT.

Authors:  K Nishimura; M Kitaichi; T Izumi; S Nagai; M Kanaoka; H Itoh
Journal:  Radiology       Date:  1992-02       Impact factor: 11.105

Review 8.  Lung clearance of 99mTc-DTPA in patients with acute lung injury and pulmonary edema.

Authors:  G Coates; H O'Brodovich; M Dolovich
Journal:  J Thorac Imaging       Date:  1988-07       Impact factor: 3.000

9.  Measures of the inflammatory response in cryptogenic fibrosing alveolitis.

Authors:  C F Pantin; S O Valind; M Sweatman; R Lawrence; C G Rhodes; L Brudin; A Britten; J M Hughes; M Turner-Warwick
Journal:  Am Rev Respir Dis       Date:  1988-11

10.  Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance.

Authors:  N K Harrison; A R Glanville; B Strickland; P L Haslam; B Corrin; B J Addis; R Lawrence; A B Millar; C M Black; M Turner-Warwick
Journal:  Respir Med       Date:  1989-09       Impact factor: 3.415

View more
  23 in total

Review 1.  The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.

Authors:  Rachel S Knipe; Andrew M Tager; James K Liao
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis.

Authors:  Xueren Li; Shouchun Peng; Luqing Wei; Zhenhua Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

5.  Gadofosveset-enhanced lung magnetic resonance imaging to detect ongoing vascular leak in pulmonary fibrosis.

Authors:  Sydney B Montesi; Rohan Rao; Lloyd L Liang; Hannah E Goulart; Amita Sharma; Subba R Digumarthy; Barry S Shea; Ravi T Seethamraju; Peter Caravan; Andrew M Tager
Journal:  Eur Respir J       Date:  2018-05-17       Impact factor: 16.671

Review 6.  Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.

Authors:  Barry S Shea; Andrew M Tager
Journal:  Proc Am Thorac Soc       Date:  2012-07

7.  Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis.

Authors:  Barry S Shea; Clemens K Probst; Patricia L Brazee; Nicholas J Rotile; Francesco Blasi; Paul H Weinreb; Katharine E Black; David E Sosnovik; Elizabeth M Van Cott; Shelia M Violette; Peter Caravan; Andrew M Tager
Journal:  JCI Insight       Date:  2017-05-04

Review 8.  New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses.

Authors:  Neil Ahluwalia; Barry S Shea; Andrew M Tager
Journal:  Am J Respir Crit Care Med       Date:  2014-10-15       Impact factor: 21.405

9.  Lung scintigraphy with nonspecific human immunoglobulin G ((99m)Tc-HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT).

Authors:  Ch Kostopoulos; J Koutsikos; C Toubanakis; L A Moulopoulos; Ch Mamoulakis; E Gialafos; P P Sfikakis; Ch Zerva; M Mavrikakis; A Leondi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-06       Impact factor: 9.236

10.  Clinical relevance of plasma prostaglandin F2α metabolite concentrations in patients with idiopathic pulmonary fibrosis.

Authors:  Kensaku Aihara; Tomohiro Handa; Toru Oga; Kizuku Watanabe; Kiminobu Tanizawa; Kohei Ikezoe; Yoshio Taguchi; Hiroe Sato; Kazuo Chin; Sonoko Nagai; Shuh Narumiya; Athol U Wells; Michiaki Mishima
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.